UCLA scientists uncork fountain of youth for HIV-fighting cells

November 15, 2004

UCLA scientists have shown that a protein called telomerase prevents the premature aging of the immune cells that fight HIV, enabling the cells to divide indefinitely and prolong their defense against infection. Published Nov. 15 in the Journal of Immunology, the research suggests a future therapy for boosting the weakened immune systems of HIV-positive people.

Every cell contains a tiny cellular clock called a telomere, which shortens each time the cell splits in two. Located at the end of the cell's chromosome, the telomere limits the number of times a cell can divide.

"Immune cells that fight HIV are under constant strain to divide in order to continue performing their protective functions. This massive amount of division shortens these cells' telomeres prematurely," explained Dr. Rita Effros, Plott Chair in Gerontology and professor of pathology and laboratory medicine at the David Geffen School of Medicine at UCLA. "So the telomeres of a 40-year-old person infected with HIV resemble those of a healthy 90-year-old person."

Most scientists agree that telomeres evolved to avert the rampant cell growth that often leads to cancer. Yet many cancers continue growing because they undergo genetic changes and start to produce telomerase, which regenerates their cells' telomeres.

Effros and first author Mirabelle Dagarag, Ph.D., hypothesized that harnessing telomerase's power over telomeres may provide a potent weapon in helping the AIDS patient's exhausted immune system defend itself against HIV. The researchers extracted immune cells from the blood of HIV-infected persons and tested what would happen if telomerase remained permanently switched on in the cell.

"By exploiting telomerase's growth influence on telomeres, we thought we might be able to keep the immune cells youthful and active as they replicated under attack," said Dagarag, a postgraduate researcher. "We used gene therapy to boost the immune cell's telomerase and then exposed the cell to HIV."

What Dagarag and Effros saw delighted them.

"We found that the immune cells could divide endlessly," said Effros, a member of the UCLA AIDS Institute. "They grew at a normal rate and didn't show any chromosomal abnormalities that might lead to cancer."

"We also saw that telomerase stabilized the telomere length," added Dagarag. "The telomere didn't shorten each time the cell divided, which left the cell able to vigorously battle HIV much longer."

The UCLA work is the first to prove that maintaining telomerase activity in immune cells from HIV-infected persons prevents telomeres from shortening.

"This is the first step toward developing other telomerase-based strategies for controlling HIV disease," said Dagarag. "Increasing the amount of telomerase in certain immune cells may one day hold the key to treating AIDS."

"To battle HIV infection effectively, we must strengthen the human immune system -- not just suppress the virus as current drugs do," said Effros. "We need a two-pronged approach to attack the disease from both sides of the medical equation."

Effros and the Geron Corporation, which collaborated on this study, are also testing several non-genetic methods of activating telomerase as potential treatments for persons infected with HIV.

The UCLA team's approach could provide the foundation for immunotherapy as a treatment for HIV and related diseases that rely on lasting protection by the same immune cells. These include cancer and latent cytomegalovirus, a viral infection that often strikes organ-transplant patients and persons with AIDS.
-end-
The study was funded by the National Institute of Allergy and Infectious Diseases, the Universitywide AIDS Research Program, the Geron Corporation and a University of California Discovery Grant.

University of California - Los Angeles

Related HIV Articles from Brightsurf:

BEAT-HIV Delaney collaboratory issues recommendations measuring persistent HIV reservoirs
Spearheaded by Wistar scientists, top worldwide HIV researchers from the BEAT-HIV Martin Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy (BEAT-HIV Collaboratory) compiled the first comprehensive set of recommendations on how to best measure the size of persistent HIV reservoirs during cure-directed clinical studies.

The Lancet HIV: Study suggests a second patient has been cured of HIV
A study of the second HIV patient to undergo successful stem cell transplantation from donors with a HIV-resistant gene, finds that there was no active viral infection in the patient's blood 30 months after they stopped anti-retroviral therapy, according to a case report published in The Lancet HIV journal and presented at CROI (Conference on Retroviruses and Opportunistic Infections).

Children with HIV score below HIV-negative peers in cognitive, motor function tests
Children who acquired HIV in utero or during birth or breastfeeding did not perform as well as their peers who do not have HIV on tests measuring cognitive ability, motor function and attention, according to a report published online today in Clinical Infectious Diseases.

Efforts to end the HIV epidemic must not ignore people already living with HIV
Efforts to prevent new HIV transmissions in the US must be accompanied by addressing HIV-associated comorbidities to improve the health of people already living with HIV, NIH experts assert in the third of a series of JAMA commentaries.

The Lancet HIV: Severe anti-LGBT legislations associated with lower testing and awareness of HIV in African countries
This first systematic review to investigate HIV testing, treatment and viral suppression in men who have sex with men in Africa finds that among the most recent studies (conducted after 2011) only half of men have been tested for HIV in the past 12 months.

The Lancet HIV: Tenfold increase in number of adolescents on HIV treatment in South Africa since 2010, but many still untreated
A new study of more than 700,000 one to 19-year olds being treated for HIV infection suggests a ten-fold increase in the number of adolescents aged 15 to 19 receiving HIV treatment in South Africa, according to results published in The Lancet HIV journal.

Starting HIV treatment in ERs may be key to ending HIV spread worldwide
In a follow-up study conducted in South Africa, Johns Hopkins Medicine researchers say they have evidence that hospital emergency departments (EDs) worldwide may be key strategic settings for curbing the spread of HIV infections in hard-to-reach populations if the EDs jump-start treatment and case management as well as diagnosis of the disease.

NIH HIV experts prioritize research to achieve sustained ART-free HIV remission
Achieving sustained remission of HIV without life-long antiretroviral therapy (ART) is a top HIV research priority, according to a new commentary in JAMA by experts at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

The Lancet HIV: PrEP implementation is associated with a rapid decline in new HIV infections
Study from Australia is the first to evaluate a population-level roll-out of pre-exposure prophylaxis (PrEP) in men who have sex with men.

Researchers date 'hibernating' HIV strains, advancing BC's leadership in HIV cure research
Researchers have developed a novel way for dating 'hibernating' HIV strains, in an advancement for HIV cure research.

Read More: HIV News and HIV Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.